Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.35 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711864 | 1.00 | TDP1 (0.35) | TDP1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL8401591 | 0.82 | ALDH1A1 (0.40) | TDP1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL29937091 | 0.82 | ALOX5AP (0.37) | ERN1PDE2ACES2ALOX5APFEN1 | |
| SCHEMBL660083 | 0.79 | ERN1 (0.58) | TDP1ALDH1A1LMNAKMT2AERN1 | |
| SCHEMBL22366835 | 0.79 | TDP1 (0.38) | TDP1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL668872 | 0.79 | PDE2A (0.41) | TDP1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL30711834 | 0.78 | CES2 (0.36) | ERN1CES2ALOX5APFEN1POLB | |
| SCHEMBL18795635 | 0.78 | CES2 (0.36) | ERN1CES2ALOX5APFEN1POLB | |
| SCHEMBL18299296 | 0.78 | ALDH1A1 (0.34) | ALDH1A1TSHRLMNAERN1CES2 | |
| SCHEMBL9340592 | 0.77 | CYP2D6 (0.38) | TDP1ALDH1A1CYP3A4HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642802-B2 | Process for the preparation of halogenated benzoic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | claimed |
| EP-2310349-B1 | PROCESS FOR THE PREPARATION OF HALOGENATED BENZOIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-04-24 | — | — | EP | claimed |
| US-20120330055-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED BENZOIC ACID DERIVATIVES | BACHMANN STEPHAN (CH) | 2012-12-27 | — | — | US | claimed |
| US-8329939-B2 | Process for the preparation of halogenated benzoic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | claimed |
| US-20120130121-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED BENZOIC ACID DERIVATIVES | BACHMANN STEPHAN (CH) | 2012-05-24 | — | — | US | claimed |
| EP-2310349-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED BENZOIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-04-20 | — | — | EP | claimed |
| WO-2009147068-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED BENZOIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-10 | — | — | WO | claimed |
| US-20090306423-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED BENZOIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-12-10 | — | — | US | claimed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-110366556-B | Antibacterial peptide macrocyclic compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3609904-B1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-11-30 | — | — | EP | disclosed |
| CN-108350028-B | Peptide macrocycles against Acinetobacter baumannii | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-1687641-A2 | TREATING NEUROPATHIC PAIN WITH NEUROPEPTIDE FF RECEPTOR 2 AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1551849-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050136444-A1 | Treating neuropathic pain with neuropeptide FF receptor 2 agonists | ACADIA PHARMACEUTICALS INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2005031000-A2 | TREATING NEUROPATHIC PAIN WITH NEUROPEPTIDE FF RECEPTOR 2 AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2004-08-19 | — | — | US | disclosed |
| WO-2004031195-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306423-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED BENZOIC ACID DERIVATIVES | CYP2F1, CYP3A5, GABRA5 | TDP1 4059/4885ALDH1A1 294/4885CYP3A4 44/4885 |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | TDP1 4511/4885ALDH1A1 4290/4885CYP3A4 3315/4885 |
| US-20120330055-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED BENZOIC ACID DERIVATIVES | CYP2F1, GABRA5, CYP3A5 | TDP1 4066/4885ALDH1A1 283/4885CYP3A4 46/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | TDP1 4511/4885ALDH1A1 4290/4885CYP3A4 3315/4885 |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | QTRT1, QTRT2, NQO2 | TDP1 1527/4885ALDH1A1 1420/4885CYP3A4 115/4885 |
| US-20120130121-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED BENZOIC ACID DERIVATIVES | CYP2F1, GABRA5, CYP3A5 | TDP1 4066/4885ALDH1A1 283/4885CYP3A4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.